Corey S. Cutler, MD, MPH, FRCPC

Articles

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8th 2022

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Identifying and Managing Steroid-Refractory Chronic GVHD

April 8th 2022

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Defining Steroid-Refractory and Steroid-Dependent GVHD

April 1st 2022

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

Frontline Treatment Options for Chronic GVHD

April 1st 2022

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

Dr. Cutler on the Examination of Itolizumab in aGVHD

March 30th 2022

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Acute vs Chronic GVHD: Identification and Stratification

March 25th 2022

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

Background on Graft-vs-Host Disease: Risk Factors and Prevention

March 25th 2022

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

The Evolving Treatment Landscape of Chronic GVHD

November 17th 2021

Closing out his discussion on chronic GVHD, Corey Cutler, MD, MPH, FRCPC, discusses belumosudil and how all 3 newly approved agents fit into the evolving treatment landscape.

REACH-3 Trial of Ruxolitinib in Steroid-Refractory Chronic GVHD

November 17th 2021

Expert insight on the study design and results of REACH-3, which tested ruxolitinib in patients with steroid-refractory chronic GVHD.

REACH-2 Trial of Ruxolitinib in Steroid-Refractory Acute GVHD

November 17th 2021

Corey Cutler, MD, MPH, FRCPC, reviews the study design and results of REACH-2, which tested ruxolitinib in patients with steroid-refractory acute GVHD.

An Overview of Treatment Options for Chronic GVHD

November 17th 2021

A comprehensive review of the treatment armamentarium for patients with chronic graft vs host disease.

An Overview of the Graft vs Host Disease Landscape

November 17th 2021

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft vs host disease and some of the factors that may put patients at higher risk.

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

March 17th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

Dr. Cutler on the Efficacy Results of the ROCKstar Study in cGVHD

March 16th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

Dr. Cutler on the Results of the ROCKstar Study in cGVHD

December 6th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses the results of the ROCKstar study in chronic graft-versus-host disease.

Dr. Cutler on Remaining Challenges in GVHD

June 2nd 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses remaining challenges in graft-versus-host disease.

Dr. Cutler on Novel Preventive Strategies Against GVHD

April 16th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Dr. Cutler on Optimizing Treatment for Acute and Chronic GVHD

March 24th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

Dr. Cutler on Treatment Options for Acute and Chronic GVHD

March 18th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.